Broker News

For brokers and producers only

Date: June 27, 2019
Market: **All** (Excludes Medicare Supplement)

FDA Approves Zolgensma

In last month's Broker News, we noted Zolgensma, a new gene therapy for spinal muscular atrophy (SMA) Type 1, was pending FDA approval. It's a one-time IV infusion which can improve a child's muscle movement and function and survival outlook. Effective May 24, 2019, Zolgensma is approved.

Next Steps
FDA approval means CareFirst members are eligible for Zolgensma under their medical benefit. Zolgensma may be administered in both inpatient and outpatient care settings, and will require prior authorization to ensure a member meets the clinical criteria.

For more information
Please refer to the May 16 Broker News for more information about Zolgensma and contact your broker sales representative for any additional questions.